Equity Profile

NTRA

Natera, Inc.

Health CareBiotechnology$44.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in the areas of reproductive health and oncology....

Key Metrics to Watch

Revenue Growth

Revenue growth is crucial for understanding the company's ability to expand its market share and improve profitability.

N/A

EPS (Earnings Per Share)

EPS provides insight into the company's profitability and is a key indicator for investors assessing financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in the areas of reproductive health and oncology. As part of the health care sector, Natera plays a significant role in advancing personalized medicine through its innovative testing solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

In Q1 2026, Natera reported an EPS of -$0.60, missing estimates by 12.78%. The stock reacted positively, gaining 2.20% the next day despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Natera's upcoming earnings, given its history of mixed results and the potential for growth in genetic testing.

Bull Case

If Natera can demonstrate strong revenue growth and improved test volumes, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to show significant growth, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the test volume be for the quarter?

Test volume is a key indicator of demand and can significantly impact revenue growth, which investors will closely monitor.

How does management plan to address the recent earnings misses?

Understanding management's strategy for improving performance is crucial for investor confidence and future stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Natera's growth in test volumes, particularly in oncology, which could drive revenue higher than anticipated.

Supporting Evidence

Historical data shows that Natera has a 50% beat rate on EPS, indicating potential for positive surprises.

The options market is pricing in a significant move, suggesting that investors expect volatility and potential upside.

Recent trends in genetic testing indicate increasing demand, which may not be fully reflected in current estimates.

Key Risk

If test volumes exceed expectations significantly, it could lead to a reevaluation of growth potential and stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it reflects the company's ability to rebound from previous earnings misses and grow its market presence.

Bull Confirmed If

Demonstrating a test volume increase of over 20% year-over-year would confirm the bull case.

Bear Confirmed If

If EPS comes in worse than -$0.70, it would validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations, history suggests a potential stock increase of around 1.81%, confirming a positive growth narrative.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors reassess future growth.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 1.41%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on test volume growth and any new product launches.
2Management's strategy for addressing past earnings misses.
3Insights into competitive positioning in the genetic testing market.
4Any commentary on partnerships or collaborations that could drive growth.
5Future guidance on revenue expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in the areas of reproductive health and oncology....

Key Metrics to Watch

Revenue Growth

Revenue growth is crucial for understanding the company's ability to expand its market share and improve profitability.

N/A

EPS (Earnings Per Share)

EPS provides insight into the company's profitability and is a key indicator for investors assessing financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

In Q1 2026, Natera reported an EPS of -$0.60, missing estimates by 12.78%. The stock reacted positively, gaining 2.20% the next day despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Natera's upcoming earnings, given its history of mixed results and the potential for growth in genetic testing.

Bull Case

If Natera can demonstrate strong revenue growth and improved test volumes, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to show significant growth, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the test volume be for the quarter?

Test volume is a key indicator of demand and can significantly impact revenue growth, which investors will closely monitor.

How does management plan to address the recent earnings misses?

Understanding management's strategy for improving performance is crucial for investor confidence and future stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Natera's growth in test volumes, particularly in oncology, which could drive revenue higher than anticipated.

Supporting Evidence

Historical data shows that Natera has a 50% beat rate on EPS, indicating potential for positive surprises.

The options market is pricing in a significant move, suggesting that investors expect volatility and potential upside.

Recent trends in genetic testing indicate increasing demand, which may not be fully reflected in current estimates.

Key Risk

If test volumes exceed expectations significantly, it could lead to a reevaluation of growth potential and stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it reflects the company's ability to rebound from previous earnings misses and grow its market presence.

Bull Confirmed If

Demonstrating a test volume increase of over 20% year-over-year would confirm the bull case.

Bear Confirmed If

If EPS comes in worse than -$0.70, it would validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations, history suggests a potential stock increase of around 1.81%, confirming a positive growth narrative.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors reassess future growth.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 1.41%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on test volume growth and any new product launches.
2Management's strategy for addressing past earnings misses.
3Insights into competitive positioning in the genetic testing market.
4Any commentary on partnerships or collaborations that could drive growth.
5Future guidance on revenue expectations for the next quarter.